A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease

Circulation Research

Volumn 106, Issue 6, 2010, Pages 1145-1152

  Ding, Hu ^a   Wu, Bin ^a   Wang, Hu ^b   Lu, Zhilan ^b   Yan, Jiangtao ^a   Wang, Xiaojing ^c   Shaffer, John R ^d   Hui, Rutai ^b   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b FUWAI HOSPITAL   (China)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Coronary heart disease; Dimethylarginine dimethylaminohydrolase 1; Polymorphism; Promoter region; Stroke

Indexed keywords

ARGININE; DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 1; MESSENGER RNA; METAL REGULATORY TRANSCRIPTION FACTOR 1; N(G),N(G) DIMETHYLARGININE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BINDING SITE; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE INSERTION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POPULATION RESEARCH; PRIORITY JOURNAL; STROKE; THROMBOSIS;

AGED; AMIDOHYDROLASES; ARGININE; ASIAN CONTINENTAL ANCESTRY GROUP; BINDING SITES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHI-SQUARE DISTRIBUTION; CHINA; CORONARY ARTERY DISEASE; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; RISK FACTORS; SEQUENCE DELETION; STROKE; THROMBOSIS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 77950975714     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.215616     Document Type: Article

References (28)

1. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation. 1997;96:379-382.
2. Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB, Wang DW, Zeldin DC. Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther. 2003;307:753-764.
3. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
4. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 2001;158:425-430.
5. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141-1146. (Pubitemid 29120084)
6. Tsao PS, Cooke JP. Endothelial alterations in hypercholesterolemia: more than simply vasodilator dysfunction. J Cardiovasc Pharmacol. 1998; 32(Suppl 3):S48-S53.
7. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens. 1997;15:901-909.
8. Goonasekera CD, Shah V, Rees DD, Dillon MJ. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma? Blood Press. 2000;9:16-21.
9. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. 2001;38:111-116.
10. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
11. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001;88:1201-1203.
12. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287: 1420-1426.
13. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127-2128.
14. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358: 2113-2117.
15. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, Whitley GS, Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol. 1996;119: 1533-1540.
16. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. Identification of two human dimethylarginine dimethyl-aminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343(Pt 1):209-214.
17. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13:198-203.
18. Song W, Chen J, Sun K, Yu H, Hui R. No association of PLIN polymorphisms with hemorrhagic and ischemic stroke. Stroke. 2008;39: 470-472.
19. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 1995;23: 4878-4884.
20. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002;303:131-137.
21. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X, Moreno V. SNPassoc: an R package to perform whole genome association studies. Bioinformatics. 2007;23:644-645.
22. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
23. Crane-Robinson C, Myers FA, Hebbes TR, Clayton AL, Thorne AW. Chromatin immunoprecipitation assays in acetylation mapping of higher eukaryotes. Methods Enzymol. 1999;304:533-547.
24. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethyl-arginine dimethylaminohydrolase. Circulation. 1999;99:3092-3095.
25. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol. 2002; 13:170-176.
26. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet. 2001;358:2096-2097.
27. Bode-Boger SM, Muke J, Surdacki A, Brabant G, Boger RH, Frolich JC. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med. 2003;8:77-81.
28. The International HapMap Project. Nature. 2003;426:789-796.